These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 28413967)

  • 21. Renal Toxicity of Systemic Therapy for Renal Cell Carcinoma.
    Jaimes EA
    Semin Nephrol; 2020 Jan; 40(1):49-58. PubMed ID: 32130966
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical role of direct renin inhibition in hypertension.
    Taylor AA; Pool JL
    Am J Ther; 2012 May; 19(3):204-10. PubMed ID: 21317620
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The 2004 Canadian recommendations for the management of hypertension: Part II--Therapy.
    Khan NA; McAlister FA; Campbell NR; Feldman RD; Rabkin S; Mahon J; Lewanczuk R; Zarnke KB; Hemmelgarn B; Lebel M; Levine M; Herbert C;
    Can J Cardiol; 2004 Jan; 20(1):41-54. PubMed ID: 14968142
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinicopathological spectrum of kidney diseases in cancer patients treated with vascular endothelial growth factor inhibitors: a report of 5 cases and review of literature.
    Usui J; Glezerman IG; Salvatore SP; Chandran CB; Flombaum CD; Seshan SV
    Hum Pathol; 2014 Sep; 45(9):1918-27. PubMed ID: 25087655
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The future of antihypertensive treatment.
    Israili ZH; Hernández-Hernández R; Valasco M
    Am J Ther; 2007; 14(2):121-34. PubMed ID: 17414579
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition of vascular endothelial growth factor-a signaling induces hypertension: examining the effect of cediranib (recentin; AZD2171) treatment on blood pressure in rat and the use of concomitant antihypertensive therapy.
    Curwen JO; Musgrove HL; Kendrew J; Richmond GH; Ogilvie DJ; Wedge SR
    Clin Cancer Res; 2008 May; 14(10):3124-31. PubMed ID: 18483380
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Are all antihypertensive drugs renoprotective?].
    Wolf S; Risler T
    Herz; 2004 May; 29(3):248-54. PubMed ID: 15167950
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Calcium channel blockers in the prevention of end stage renal disease: a review.
    Derwa A; Peeters P; Vanholder R
    Acta Clin Belg; 2004; 59(1):44-56. PubMed ID: 15065696
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The emerging role of vascular endothelial growth factor (VEGF) in vascular homeostasis: lessons from recent trials with anti-VEGF drugs.
    Thanigaimani S; Kichenadasse G; Mangoni AA
    Curr Vasc Pharmacol; 2011 May; 9(3):358-80. PubMed ID: 20807189
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Follow-up of Antihypertensive Therapy Improves Blood Pressure Control: Results of HYT (HYperTension survey) Follow-up.
    Fici F; Seravalle G; Koylan N; Nalbantgil I; Cagla N; Korkut Y; Quarti-Trevano F; Makel W; Grassi G
    High Blood Press Cardiovasc Prev; 2017 Sep; 24(3):289-296. PubMed ID: 28497339
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Team-Based Approach to Management of Hypertension Associated with Angiogenesis Inhibitors.
    Patel S; Dushenkov A; Jungsuwadee P; Krishnaswami A; Barac A
    J Cardiovasc Transl Res; 2020 Jun; 13(3):463-477. PubMed ID: 32430701
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bevacizumab-induced hypertension: pathogenesis and management.
    Syrigos KN; Karapanagiotou E; Boura P; Manegold C; Harrington K
    BioDrugs; 2011 Jun; 25(3):159-69. PubMed ID: 21627340
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hypertension as a surrogate marker for the activity of anti-VEGF agents.
    Mir O; Ropert S; Alexandre J; Goldwasser F
    Ann Oncol; 2009 May; 20(5):967-70. PubMed ID: 19403940
    [No Abstract]   [Full Text] [Related]  

  • 34. Renal toxicity of anticancer agents targeting vascular endothelial growth factor (VEGF) and its receptors (VEGFRs).
    Cosmai L; Gallieni M; Liguigli W; Porta C
    J Nephrol; 2017 Apr; 30(2):171-180. PubMed ID: 27154025
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Aflibercept (VEGF Trap): one more double-edged sword of anti-VEGF therapy for cancer?
    Jin K; Shen Y; He K; Xu Z; Li G; Teng L
    Clin Transl Oncol; 2010 Aug; 12(8):526-32. PubMed ID: 20709650
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Trends in antihypertensive treatment--lessons from the National Acute Stroke Israeli (NASIS) registry.
    Koifman E; Tanne D; Molshatzki N; Leibowitz A; Grossman E
    Blood Press; 2014 Oct; 23(5):262-9. PubMed ID: 24483945
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Beyond blood pressure: evidence for cardiovascular, cerebrovascular, and renal protective effects of renin-angiotensin system blockers.
    Verdecchia P; Gentile G; Angeli F; Reboldi G
    Ther Adv Cardiovasc Dis; 2012 Apr; 6(2):81-91. PubMed ID: 22528743
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Proteinuria and hypertension in patients treated with inhibitors of the VEGF signalling pathway--incidence, mechanisms and management.
    Tesařová P; Tesař V
    Folia Biol (Praha); 2013; 59(1):15-25. PubMed ID: 23537524
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of antihypertensive therapy with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers in combination with calcium channel blockers for stroke prevention.
    Talbert RL
    J Am Pharm Assoc (2003); 2010; 50(5):e116-25. PubMed ID: 20833609
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway.
    Hamnvik OP; Choueiri TK; Turchin A; McKay RR; Goyal L; Davis M; Kaymakcalan MD; Williams JS
    Cancer; 2015 Jan; 121(2):311-9. PubMed ID: 25236375
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.